biotech

Exelixis Cancer Treatment Hits Key Milestone

Exelixis Inc. (NASDAQ: EXEL) kicked off the week with a couple updates that are already having a big impact on the stock. These updates came in the form of a ...
Read Full Story »

Is Spark Therapeutics’ Luxturna a Game Changer?

Shares of Spark Therapeutics Inc. (NASDAQ: ONCE) saw a handy gain to close out the week after the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue and Gene Therapies Advisory ...
Read Full Story »

Are Analysts Secretly Calling Gilead a Screaming Buy?

Sometimes it turns out that great growth companies eventually run into the day when getting the growth of the past is not possible. That has been the case of Gilead ...
Read Full Story »

Why Infinity Pharmaceuticals Shares Are Surging

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) saw its shares almost double early on Thursday after the company announced that an abstract from its ongoing clinical trial of IPI-549 had been selected ...
Read Full Story »

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the most recent settlement date, September 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Why AnaptysBio Is One of Tuesday’s Top Stocks

AnaptysBio Inc. (NASDAQ: ANAB) is easily one of the best performing stocks on Tuesday, with its shares jumping over 70% in this session. Although the company has only been public ...
Read Full Story »

Even More Biopharma and FDA Catalysts Coming in October

As the markets continue to hit all-time highs, biotech and pharmaceutical companies have been part of these massive gains. There is a very positive sentiment in the health care sector ...
Read Full Story »

4 Biotech Stocks to Buy That May See Huge Volatility From Earnings

With the third-quarter earnings reporting season upon us, investors are checking their holdings and research to see just how things are shaping up for stocks they own. One thing is ...
Read Full Story »

Why ImmunoGen’s Secondary Makes Sense

ImmunoGen Inc. (NASDAQ: IMGN) saw its shares make a sharp turn downward early Thursday morning after the stock has seen an incredible year of trading so far. Shares taking a ...
Read Full Story »

What CytomX Gets From Its Huge Amgen Collaboration

CytomX Therapeutics Inc. (NASDAQ: CTMX) shares saw a solid gain in Wednesday’s session following announcement of a strategic collaboration with Amgen Inc. (NASDAQ: AMGN) in immuno-oncology. The companies are planning ...
Read Full Story »

Amicus Therapeutics Wins Big at World Muscle Society Conference

Amicus Therapeutics Inc. (NASDAQ: FOLD) is another biotech player that’s seeing a nice boost from the World Muscle Society Conference in France. In this case, the company announced additional positive ...
Read Full Story »

Why Catabasis Shares Are Surging

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) shares continued their incredible climb after the firm announced positive efficacy results from its MoveDMD trial in Duchenne muscular dystrophy (DMD). These results were presented ...
Read Full Story »

Credit Suisse Identifies Top Mid-Large Cap Biotech and Pharma Stocks for Big Upside

U.S. pharmaceutical and biotech stocks may have considerable upside if Credit Suisse's views come to pass. The firm is looking at pharma and biotech opportunities around politics, drug pipelines and ...
Read Full Story »

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Shares of Sarepta Therapeutics Inc. (NASDAQ: SRPT) saw a handy gain on Monday after the firm received an upgrade from Morgan Stanley. The driving force behind this upgrade is Sarepta’s ...
Read Full Story »

Why Endocyte Is Monday’s Biggest Winner

Endocyte Inc. (NASDAQ: ECYT) kicked off the week with an incredible gain, making it one of the best, if not the best, performing stocks in Monday’s session. This massive gain ...
Read Full Story »